Biokeys Pharmaceuticals Inc. Announces National Institute of Health License.

Business Editors & Health/Medical Writers

BIOWIRE2K

Biokeys Pharmaceuticals Inc. (OTCBB:BKYS) announced today that the Company has been granted an exclusive, worldwide sub-license by the United States Public Health Service National Institute of Health (NIH) for U.S. Patent

number 5,562,905. The technology covered by this patent complements patents and technology licensed by the Company from The University of Texas M.D. Anderson Cancer Center for the development of BlockAide/CR(TM), an HIV viral entry inhibitor. BlockAide/CR is designed to augment currently available "triple combination" HAART Therapy, especially in the increasing number of patients who show resistance to current HIV drugs. "Triple combination" drugs are prescribed to limit viral replication in already HIV-infected immune system cells. In contrast, viral entry inhibitors prevent HIV from entering and infecting these cells in the first place. In Company-sponsored primate trials, BlockAide/CR has shown the ability to drastically reduce HIV viral loads. Chairman-designate of Biokeys Pharmaceuticals, and former president and CEO of Trimeris Inc. (NasdaqNM:TRMS), Dr. M. Ross Johnson, Ph.D., said, "We believe that BlockAide/CR holds promise as a drug candidate for the new 'fourth modality' for treating HIV/AIDS patients. We have therefore begun preparations for human trials to verify its safety."

Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading-edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses its energy in cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. The Company's lead anticancer compound, CoFactor(TM), is a chemotherapy biomodulator designed to be used in conjunction with 5-FU, the world's most frequently used cancer drug. CoFactor is being readied to enter Phase II/III human clinical trials in the U.S. and Europe. Also in development is EradicAide(TM), a cell-mediated, antibody-negative therapeutic vaccine for HIV infection/AIDS. In primate trials, EradicAide has demonstrated the ability to reduce HIV viral loads to undetectable levels, reduce HIV transmissibility and delay progression to AIDS.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.

L.G. Zangani, LLC provides financial public relations service to the Company. As such, L.G. Zangani, LLC, and/or its officers, agents and employees, receives remuneration for public relations and or other services in the form of moneys, capital stock in the Company, warrants or options to purchase capital in the Company.